Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases

Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors

Joeri Auwerx, Thomas W. North, Bradley D. Preston, George J. Klarmann, Erik De Clercq, Jan Balzarini

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and do not inhibit HIV-2. Given that the amino acids lining the NNRTI-specific pocket of HIV-1 RT display higher similarity to the corresponding feline immunodeficiency virus (FIV) RT amino acids than to HIV-2 RT, the susceptibility of FIV RT and chimeric HIV-1/FIV RTs to NNRTIs and the role of the p51 subunit in the inhibitory action of NNRTIs were investigated. We found that the wild-type FIV RT and the FIVp66/HIVp51 chimeric enzyme showed no susceptibility for NNRTIs. On the other hand, the chimeric HIVp66/FIVp51 RT retained a sensitivity spectrum for NNRTIs similar to that of the wild-type HIV-1 RT. The noncompetitive nature of inhibition of HIV-1 RT by nevirapine was also observed with the HIVp66/ FIVp51 chimeric enzyme. Inhibition of the chimeric RTs by nucleoside reverse transcriptase inhibitors and foscarnet was in the same range as observed for the corresponding HIVp66/HIVp51 and FIVp66/FIVp51 wild-type enzymes. The chimeric RTs had an affinity (Km) for their dNTP substrate and template/primer comparable with that of the wild-type HIV-1 and FIV RTs, but their catalytic efficacy (kcat) was markedly decreased. This decreased catalytic efficacy of the RT chimeras may suggest suboptimal interactions between p66 and p51 in the chimeric enzymes. Our results point to a minor role of the p51 subunit in the sensitivity to RT inhibitors.

Original languageEnglish (US)
Pages (from-to)400-406
Number of pages7
JournalMolecular Pharmacology
Volume61
Issue number2
DOIs
StatePublished - 2002

Fingerprint

Feline Immunodeficiency Virus
Reverse Transcriptase Inhibitors
RNA-Directed DNA Polymerase
HIV-1
Enzymes
Foscarnet
Nevirapine
Amino Acids
HIV-2
Nucleosides
Human immunodeficiency virus 1 reverse transcriptase

ASJC Scopus subject areas

  • Pharmacology

Cite this

Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases : Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors. / Auwerx, Joeri; North, Thomas W.; Preston, Bradley D.; Klarmann, George J.; De Clercq, Erik; Balzarini, Jan.

In: Molecular Pharmacology, Vol. 61, No. 2, 2002, p. 400-406.

Research output: Contribution to journalArticle

Auwerx, Joeri ; North, Thomas W. ; Preston, Bradley D. ; Klarmann, George J. ; De Clercq, Erik ; Balzarini, Jan. / Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases : Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors. In: Molecular Pharmacology. 2002 ; Vol. 61, No. 2. pp. 400-406.
@article{99df403653324f58bca4b7191491d031,
title = "Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors",
abstract = "Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and do not inhibit HIV-2. Given that the amino acids lining the NNRTI-specific pocket of HIV-1 RT display higher similarity to the corresponding feline immunodeficiency virus (FIV) RT amino acids than to HIV-2 RT, the susceptibility of FIV RT and chimeric HIV-1/FIV RTs to NNRTIs and the role of the p51 subunit in the inhibitory action of NNRTIs were investigated. We found that the wild-type FIV RT and the FIVp66/HIVp51 chimeric enzyme showed no susceptibility for NNRTIs. On the other hand, the chimeric HIVp66/FIVp51 RT retained a sensitivity spectrum for NNRTIs similar to that of the wild-type HIV-1 RT. The noncompetitive nature of inhibition of HIV-1 RT by nevirapine was also observed with the HIVp66/ FIVp51 chimeric enzyme. Inhibition of the chimeric RTs by nucleoside reverse transcriptase inhibitors and foscarnet was in the same range as observed for the corresponding HIVp66/HIVp51 and FIVp66/FIVp51 wild-type enzymes. The chimeric RTs had an affinity (Km) for their dNTP substrate and template/primer comparable with that of the wild-type HIV-1 and FIV RTs, but their catalytic efficacy (kcat) was markedly decreased. This decreased catalytic efficacy of the RT chimeras may suggest suboptimal interactions between p66 and p51 in the chimeric enzymes. Our results point to a minor role of the p51 subunit in the sensitivity to RT inhibitors.",
author = "Joeri Auwerx and North, {Thomas W.} and Preston, {Bradley D.} and Klarmann, {George J.} and {De Clercq}, Erik and Jan Balzarini",
year = "2002",
doi = "10.1124/mol.61.2.400",
language = "English (US)",
volume = "61",
pages = "400--406",
journal = "Molecular Pharmacology",
issn = "0026-895X",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "2",

}

TY - JOUR

T1 - Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases

T2 - Role of the subunits in resistance/sensitivity to non-nucleoside reverse transcriptase inhibitors

AU - Auwerx, Joeri

AU - North, Thomas W.

AU - Preston, Bradley D.

AU - Klarmann, George J.

AU - De Clercq, Erik

AU - Balzarini, Jan

PY - 2002

Y1 - 2002

N2 - Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and do not inhibit HIV-2. Given that the amino acids lining the NNRTI-specific pocket of HIV-1 RT display higher similarity to the corresponding feline immunodeficiency virus (FIV) RT amino acids than to HIV-2 RT, the susceptibility of FIV RT and chimeric HIV-1/FIV RTs to NNRTIs and the role of the p51 subunit in the inhibitory action of NNRTIs were investigated. We found that the wild-type FIV RT and the FIVp66/HIVp51 chimeric enzyme showed no susceptibility for NNRTIs. On the other hand, the chimeric HIVp66/FIVp51 RT retained a sensitivity spectrum for NNRTIs similar to that of the wild-type HIV-1 RT. The noncompetitive nature of inhibition of HIV-1 RT by nevirapine was also observed with the HIVp66/ FIVp51 chimeric enzyme. Inhibition of the chimeric RTs by nucleoside reverse transcriptase inhibitors and foscarnet was in the same range as observed for the corresponding HIVp66/HIVp51 and FIVp66/FIVp51 wild-type enzymes. The chimeric RTs had an affinity (Km) for their dNTP substrate and template/primer comparable with that of the wild-type HIV-1 and FIV RTs, but their catalytic efficacy (kcat) was markedly decreased. This decreased catalytic efficacy of the RT chimeras may suggest suboptimal interactions between p66 and p51 in the chimeric enzymes. Our results point to a minor role of the p51 subunit in the sensitivity to RT inhibitors.

AB - Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are specific for human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and do not inhibit HIV-2. Given that the amino acids lining the NNRTI-specific pocket of HIV-1 RT display higher similarity to the corresponding feline immunodeficiency virus (FIV) RT amino acids than to HIV-2 RT, the susceptibility of FIV RT and chimeric HIV-1/FIV RTs to NNRTIs and the role of the p51 subunit in the inhibitory action of NNRTIs were investigated. We found that the wild-type FIV RT and the FIVp66/HIVp51 chimeric enzyme showed no susceptibility for NNRTIs. On the other hand, the chimeric HIVp66/FIVp51 RT retained a sensitivity spectrum for NNRTIs similar to that of the wild-type HIV-1 RT. The noncompetitive nature of inhibition of HIV-1 RT by nevirapine was also observed with the HIVp66/ FIVp51 chimeric enzyme. Inhibition of the chimeric RTs by nucleoside reverse transcriptase inhibitors and foscarnet was in the same range as observed for the corresponding HIVp66/HIVp51 and FIVp66/FIVp51 wild-type enzymes. The chimeric RTs had an affinity (Km) for their dNTP substrate and template/primer comparable with that of the wild-type HIV-1 and FIV RTs, but their catalytic efficacy (kcat) was markedly decreased. This decreased catalytic efficacy of the RT chimeras may suggest suboptimal interactions between p66 and p51 in the chimeric enzymes. Our results point to a minor role of the p51 subunit in the sensitivity to RT inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=0036156328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036156328&partnerID=8YFLogxK

U2 - 10.1124/mol.61.2.400

DO - 10.1124/mol.61.2.400

M3 - Article

VL - 61

SP - 400

EP - 406

JO - Molecular Pharmacology

JF - Molecular Pharmacology

SN - 0026-895X

IS - 2

ER -